Highest-materiality recent filing
Ironwood CFO Gregory Martini resigns; Ronald Silver named interim CFO
Gregory Martini resigns as SVP, CFO effective May 15, 2026, not due to any disagreement with the company on financial reporting.
Ironwood Q1 2026: Revenue $107M (+159% YoY); GAAP EPS $0.25 from -$0.23; LINZESS sales $273M (+97%)
GAAP net income $41M ($0.25 basic EPS) vs loss $37M ($0.23 loss) in Q1 2025.
Ironwood Q4 revenue $47.7M, GAAP net loss $2.3M; FY adj EBITDA $138M, guides FY26 >$300M
Full-year 2025 total revenue $296M, GAAP net income $24M ($0.15 diluted EPS), adjusted EBITDA $138M.
Ironwood issues FY 2026 guidance; LINZESS net sales targeted at $1.125-1.175B
FY 2026 LINZESS U.S. net sales guided at $1.125B-$1.175B; total revenue $450M-$475M.
Ironwood subsidiary settles Ferring IP litigation with $12.5M payment, license amendment
VectivBio to pay Ferring $12.5M ($7.5M upfront, $5M by Dec 31, 2026) under amended license.
HHS sets LINZESS Maximum Fair Price at $136 per 30-day supply starting Jan 2027
MFP for LINZESS (linaclotide) is $136 for a 30-day supply, effective January 1, 2027.
Ironwood Q3 LINZESS sales up 40% YoY to $315M; raises full-year guidance
Q3 GAAP net income $40M ($0.23 diluted EPS) vs $3.6M a year ago; adjusted EBITDA $82M vs $34.5M.
LINZESS generated $248M in U.S. net sales in Q2 2025, with 10% year-over-year EUTRx demand growth.
Ironwood dismisses EY as auditor; appoints KPMG; prior adverse ICFR opinion cited
Dismissed Ernst & Young as independent auditor on July 3, 2025; no disagreements during fiscal 2023 and 2024.
Received deficiency letter on May 28, 2025 for bid price below $1.00 for 30 consecutive business days.
Ironwood Q1 net loss $37.4M; revenue down 45% YoY; raises adjusted EBITDA guidance to >$105M
Total revenue of $41.1M vs $74.9M in Q1 2024, down 45% YoY.
Ironwood reiterates FY2025 LINZESS guidance, raises EBITDA to >$105M; Q1 net sales down 46%
Reiterates FY2025 LINZESS U.S. net sales guidance of $800-$850M and total revenue of $260-$290M.
FDA requires confirmatory Phase 3 trial for apraglutide; Ironwood explores strategic alternatives
FDA feedback indicates a confirmatory Phase 3 trial is needed to seek approval of apraglutide for SBS-IF; company will work on design and regulatory path.
Ironwood FY2024 revenue $351M, net income positive; apraglutide NDA rolling initiated
Total revenue $90.5M in Q4 and $351.4M for FY2024, down 23% YoY from $442.7M in FY2023.
Ironwood cuts workforce ~50%, promotes Gregory Martini to CFO
Workforce reduction of ~50% approved Jan 17, targeting primarily field-based sales employees; affected employees notified Jan 29.
Ironwood CFO Sravan Emany resigns effective Dec 18; CEO McCourt interim PFO
Sravan Emany resigns as SVP, COO, and CFO effective Dec 18, 2024.
Ironwood Q3 revenue down 19% YoY to $91.6M; LINZESS Rx demand +13%
GAAP net income $3.6M ($0.02 diluted EPS) vs $15.3M ($0.10) a year ago.
Ironwood amends credit facility to $550M, extends maturity to 2028; declines CNP-104 option
Revolving credit facility increased from $500M to $550M; $400M outstanding as of amendment date.
Ironwood Q2 revenue down 12% to $94.4M; cuts FY 2024 guidance on Medicaid pricing
Total revenue $94.4M in Q2 2024, down 12% from $107.4M in Q2 2023; FY 2024 guidance revised lower due to pricing pressure.
Ironwood repays $200M convertible notes at maturity using cash and revolver; CFO adds COO role
Repaid $200M 0.75% Convertible Senior Notes due 2024 on June 17 using $50M cash and $150M from $500M revolver.
Ironwood Q1 revenue down 28% YoY, net loss $4.2M; apraglutide Phase III positive
Q1 total revenue $74.9M vs $104.1M YoY; GAAP net loss of $4.2M vs net income of $45.7M.
Ironwood reports FY2023 GAAP net loss of $1.0B; LINZESS sales $1.1B (+7%)
FY2023 total revenue $442.7M; LINZESS collaboration revenue $430M; Q4 revenue $117.6M.
Ironwood guides FY2024 adj EBITDA >$150M, LINZESS low-single digit growth, pipeline catalysts
Maintains FY2023 guidance: LINZESS net sales growth 6-8%, revenue $435-450M, adjusted EBITDA ~($900M) from VectivBio charge.
Ironwood posts Q2 GAAP net loss of $1.06B on acquisition costs; LINZESS sales +9%
GAAP net loss attributable to Ironwood of $1.06B, or $6.84/share diluted, primarily from VectivBio acquisition.
Ironwood completes $1.15B tender offer for VectivBio, acquires ~97.6% of shares
Tendered 59.3M shares represent ~94.4% plus 2.0M via guaranteed delivery (~97.6% total).
Ironwood to acquire VectivBio for $17.00/share; secures $500M credit facility
Cash tender offer at $17.00/share for all VectivBio shares; minimum tender condition >80%.
Ironwood Q1 2023: net income $45.7M ($0.30 EPS); LINZESS demand up 10% YoY
Total revenues $104.1M, up 7% YoY; GAAP net income $45.7M vs $38.8M.
FY 2022 total revenues $410.6M (down ~1% YoY); GAAP net income $175.1M vs $528.4M in FY 2021.
Updated FY2022: total revenue ~$411M (prev. $420-430M), LINZESS net sales ~0% growth, adj. EBITDA ~$250M.
Ironwood Q3 GAAP net income $50M; LINZESS Rx demand up 10% YoY, surpasses 1M quarterly scripts
GAAP net income of $50M ($0.28 diluted EPS); adjusted EBITDA $69M; total revenue $108.6M vs. $103.7M YoY.
Ironwood Q2 2022 GAAP net income $37M; LINZESS Rx demand up 9% YoY; guidance reiterated
GAAP net income of $37M ($0.21 diluted EPS); adjusted EBITDA of $56M; total revenue $97.2M, down 7% YoY.
Ironwood Q1 2022: LINZESS Rx demand +11%; net sales $232M; GAAP net income $39M
LINZESS U.S. net sales $232M (+8% YoY); prescription demand growth +11% YoY.
Ironwood Q4/FY2021: LINZESS blockbuster >$1B; total revenue $414M; pipeline advances
FY2021 total revenue $414M (driven by $400M LINZESS collab revenue); GAAP net income $528M (incl $338M tax benefit).
LINZESS U.S. net sales expected to surpass $1B in 2021, achieving blockbuster status.
On May 19, 2026, in connection with Mr. Silver’s new role as the Company’s interim chief financial officer and principal financial officer, the Committee approved a monthly interim assignment fee of $12,250
Effective May 15, 2026, Ronald Silver, age 44, the Company’s Senior Vice President, Corporate Controller and Chief Accounting Officer, will also serve as the Company’s interim chief financial officer and principal financial officer.
On May 8, 2026, Gregory Martini notified Ironwood Pharmaceuticals, Inc. (the “Company”) that he is resigning from his position as Senior Vice President, Chief Financial Officer, effective May 15, 2026.
the Company announced the promotion of Gregory Martini, 36, to Senior Vice President, Chief Financial Officer.
Mr. Martini will assume the responsibilities of the Company’s principal financial officer from Thomas McCourt, who will remain the Company’s principal executive officer.
Andrew Davis notified Ironwood Pharmaceuticals, Inc. (the “Company”) that he is resigning from his position as Senior Vice President, Chief Business Officer, effective November 22, 2024.
On June 18, 2024, the Board of Directors of Ironwood Pharmaceuticals, Inc. (the “Company”) appointed Sravan K. Emany, age 46, the Company’s Senior Vice President, Chief Financial Officer, to the position of Senior Vice President, Chief Operating Officer and Chief Financial Officer, effective immediately.
Accordingly, Jason Rickard’s last day as Senior Vice President, Chief Operating Officer, and as an employee of the Company, will be May 12, 2023.
On November 29, 2021, the Board of Directors of Ironwood Pharmaceuticals, Inc. (the “Company”) appointed Sravan K. Emany, 44, as the Company’s Senior Vice President, Chief Financial Officer, effective December 6, 2021 (the “Effective Date”).
Max materiality 0.90 · Median 0.65 · Most common event earnings